OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Reviews is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Clinical burden of hemophilia in older adults: Beyond bleeding risk	143
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	94
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	62
Editorial Board	58
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	57
Advances in the critical care management for patients with hematological malignancies	56
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	56
Radiation and leukaemia: Which leukaemias and what doses?	56
Not all LGL leukemias are created equal	53
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	53
Artificial intelligence in sickle disease	50
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	50
Thalassaemia in China	49
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	47
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	43
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	41
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	41
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	41
Chasing leukemia differentiation through induction therapy, relapse and transplantation	40
Adenovirus infection in adult allogeneic hematopoietic stem cell transplant recipients: Systematic review and meta-analysis	40
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	39
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	38
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia	37
Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia	34
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	34

Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	33
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	32
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	32
Endothelial cells: major players in acute myeloid leukaemia	31
Preservation of fertility in female patients with hematologic diseases	30
Old tests and new paradigms: How to interpret iron studies and related biomarkers for the diagnosis of iron deficiency in adults	30
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	30